Concurrent overexpression of p53 and c-erbB-2 correlates with accelerated cycling and concomitant poor prognosis in node-negative breast cancer

Human Pathology

Volumn 32, Issue 3, 2001, Pages 311-319

  Rudolph, Pierre ^a   Alm, Per ^a   Olsson, Håkan ^a   Heidebrecht, Hans Juergen ^a   Fernö, Mårten ^a   Baldetorp, B ^a   Parwaresch, Reza ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

Breast cancer; c erbB 2; Cell cycle; Ki S2; p53; Prognosis

Indexed keywords

MONOCLONAL ANTIBODY; ONCOPROTEIN; PROTEIN P53;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER SURVIVAL; CELL CYCLE; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; ONCOGENE C ERB; PROGNOSIS;

EID: 0035087639     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1053/hupa.2001.22748     Document Type: Article

References (62)

1. The 1993 Walter Hubert Lecture: The role of the p53 tumour-suppressor gene in tumorigenesis
2. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene
3. The neu gene: An erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor
4. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
5. Loss of heterozygosity at the TP53 gene: Independent occurrence from genetic instability events in node-negative breast cancer
6. Studies of the HER-2/neu proto-oncogene in human breast cancer
7. Increased erbB-2 gene copies and expression in multiple stages of breast cancer
8. Expression of the erbB-2 family of growth factor receptors and their ligands in breast cancers. Implication for tumor biology and clinical behavior
9. Mdm2: Keeping p53 under control
10. Diagnostic assessment of two novel proliferation-specific antigens in benign and malignant melanocytic lesions
11. Monoclonal antibodies Ki-S3 and Ki-S5 yield new data on the "Ki-67" proteins
12. Prognostic significance of the proliferative activity in neuroblastoma
13. The immunohistochemical marker Ki-S2: Tissue distribution and cell cycle kinetics of a novel proliferation-specific antigen
14. 2 and M
15. Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer. The influence of the pattern of immunostaining and adjuvant therapy
16. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer
17. ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer
18. p53 and c-erbB2 as markers of resistance to adjuvant chemotherapy in breast cancer
19. Improved method for assay of estradiol and progesterone receptors with special reference to breast cancer
20. Histological grading and prognosis in breast cancer
21. Moist autoclaving. A simplified method for antigen unmasking
22. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: A comparison between ABC and unlabeled antibody (PAP) procedures
23. Relationship between p53 gene abnormalities and other tumour characteristics in breast-cancer prognosis
24. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients
25. Age as a prognostic factor in breast cancer
26. Indicators of prognosis in node-negative breast cancer
27. Statistical aspects of prognostic factor studies in oncology
28. Dangers of using "optimal" cutpoints in the evaluation of prognostic factors
29. Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer
30. The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: A paradigm for the development of other macromolecular markers - A review
31. p53 in node-negative breast carcinoma: An immunohistochemical study of epidemiologic risk factors, histologic features, and prognosis
32. Overexpression of p53 and HER-2/neu proteins as prognostic markers in early stage breast cancer
33. Node-negative breast cancers with p53(-)/HER2-neu(-) status may identify women with very good prognosis
34. Prognostic significance of the co-expression of p53 and c-erbB-2 proteins in breast cancer
35. Prospective studies of p53 and c-erbB-2 expression in relation to clinicopathological parameters of human ductal breast cancer in the second stage of clinical advancement
36. Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients
37. The cell cycle - Theory and applications to cancer
38. Structure and expression of c-erbB-2 and EGF receptor genes in inflammatory and non-inflammatory breast cancer: Prognostic significance
39. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in h uman breast cancer cells
40. Oncogenes and the strategy of growth factors
41. Tumour suppressors, kinases and clamps: How p53 regulates the cell cycle in response to DNA damage
42. Cell cycle expression and p53 regulation of the cyclin-dependent kinase inhibitor p21
43. p53-induced p21 controls DNA replication
44. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis
45. p53-dependent repression of cdk4 synthesis in transforming growth factor-beta-induced G1 cell cycle arrest
46. Inhibition of DNA topoisomerase II alpha gene expression by the p53 tumor suppressor
47. p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells
48. p53-dependent apoptosis suppresses tumor growth and progression in vivo
49. Mdm2 promotes the rapid degradation of p53
50. Regulation of p53 stability by Mdm2
51. A prospective study of the significance of gene and chromosome alterations as prognostic indicators of breast cancer patients with lymph node metastases
52. Neu/ERBB2 cooperates with p53-172H during mammary tumorigenesis in transgenic mice
53. Prognostic significance of Ki-67 and topoisomerase II alpha expression in infiltrating ductal breast cancer. A multivariate analysis of 863 cases
54. Correlation between p53, c-erbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status, and proliferation in 356 node-negative ductal invasive carcinomas of the breast: Prognostic implications
55. The cell cycle in breast cancer
56. Inhibitors of mammalian G1 cyclin-dependent kinases
57. G1 control in mammalian cells
58. Formation and activation of a cyclin E-cdk2 complex during the G1 phase of the human cell cycle
59. Association of human cyclin E with a periodic G1-S phase protein kinase
60. Decreased levels of the cell-cycle inhibitor p27Kip1 protein: Prognostic implications in primary breast cancer
61. Immunologic proliferation marker Ki-S2 as prognostic indicator for lymph node-negative breast cancer
62. Prognostic factors and treatment decisions in axillary-node-negative breast cancer